<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACEON- perindopril erbumine tablet </strong><br>Symplmed, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use ACEON<span class="Sup">®</span> safely and effectively. See full prescribing information for ACEON.</span><br><span class="Bold">ACEON (perindopril erbumine) 2, 4 and 8 mg Tablets</span><br><span class="Bold">Initial U.S. Approval: 1993</span>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: FETAL TOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li>
<span class="Bold">When pregnancy is detected, discontinue ACEON as soon as possible.</span> (<a href="#splSection9">5.4</a>)</li>
<li>
<span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus.</span> (<a href="#splSection9">5.4</a>)</li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: FETAL TOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li>
<span class="Bold">When pregnancy is detected, discontinue ACEON as soon as possible.</span> (<a href="#splSection9">5.4</a>)</li>
<li>
<span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus.</span> (<a href="#splSection9">5.4</a>)</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul class="Disc">
<li>ACEON is indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> (<a href="#splSection1">1.1</a>)</li>
<li>ACEON is indicated for treatment of patients with stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> to reduce the risk of cardiovascular mortality or nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<a href="#splSection2">1.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </p>
<ul class="Disc"><li>The recommended initial dose is 4 mg once a day. The dosage may be titrated upward until blood pressure, when measured just before the next dose, is controlled or to a maximum of 16 mg per day (<a href="#splSection3">2.1</a>)</li></ul>
<p class="Highlighta">Stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span> </p>
<ul class="Disc"><li>ACEON should be given at an initial dose of 4 mg once daily for 2 weeks, and then increased, as tolerated, to a maintenance dose of 8 mg once daily (<a href="#splSection4">2.2</a>)</li></ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets: 2, 4 and 8 mg (<a href="#splSectionPLRDosageFormsStrength">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (<a href="#splSectionPLRContraindications">4.0</a>, <a href="#splSection6">5.1</a>)</li>
<li>Do not co-administer aliskiren with ACEON in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (<a href="#splSectionPLRContraindications">4.0</a>, <a href="#splSection32">7.8</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Watch for <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (<a href="#splSection6">5.1</a>)</li>
<li>Monitor renal function during therapy (<a href="#splSection13">5.8</a>)</li>
<li>Assess for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (<a href="#splSection7">5.2</a>, <a href="#splSection11">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>:</span> Most common adverse events (incidence greater than or equal to 5%) are <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (<a href="#splSection15">6.1</a>)</li>
<li>
<span class="Bold">Stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span>:</span> Most common adverse events leading to discontinuation were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4240582" conceptname="Drug intolerance">drug intolerance</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<a href="#splSection15">6.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Symplmed, LLC. at 1-888-985-7657 or FDA at 1-800-FDA-1088 or www.FDA.gov/Medwatch.
</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Diuretics: Excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> (<a href="#splSection18">7.1</a>)</li>
<li>Potassium-sparing diuretics/potassium supplements: <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> (<a href="#splSection19">7.2</a>)</li>
<li>Lithium: Increase serum lithium levels, symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> (<a href="#splSection20">7.3</a>)</li>
<li>Injectable gold: Nitritoid reactions (<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) (<a href="#splSection21">7.4</a>)</li>
<li>NSAID use may lead to increased risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and loss of antihypertensive effect (<a href="#splSection31">7.7</a>)</li>
<li>Dual inhibition of the renin-angiotensin system: Increased risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (<a href="#splSection32">7.8</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Geriatrics: Start at low daily dose (4 mg or less) and titrate slowly as needed. Experience with doses exceeding 8 mg is limited (<a href="#splSectionPLRGeriatric">8.5</a>)</li>
<li>Dosage adjustment may be necessary in renally impaired patients (<a href="#splSection26">8.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">
WARNING: FETAL TOXICITY
</a></h1>
<h1><a href="#section-1" class="toc">
1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">
1.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</a></h2>
<h2><a href="#section-1.2" class="toc">
1.2 Stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span>
</a></h2>
<h1><a href="#section-2" class="toc">
2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">
2.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</a></h2>
<h2><a href="#section-2.2" class="toc">
2.2 Stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span>
</a></h2>
<h2><a href="#section-2.3" class="toc">
2.3 Dose Adjustment in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> and Dialysis
</a></h2>
<h1><a href="#section-3" class="toc">
3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">
4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">
5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">
5.1 Anaphylactoid and Possibly Related Reactions
</a></h2>
<h2><a href="#section-5.2" class="toc">
5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">
5.3 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">
5.4 Fetal Toxicity
</a></h2>
<h2><a href="#section-5.5" class="toc">
5.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>
</a></h2>
<h2><a href="#section-5.6" class="toc">
5.6 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>
</a></h2>
<h2><a href="#section-5.7" class="toc">
5.7 <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>
</a></h2>
<h2><a href="#section-5.8" class="toc">
5.8 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span>
</a></h2>
<h2><a href="#section-5.9" class="toc">
5.9 Surgery/Anesthesia
</a></h2>
<h1><a href="#section-6" class="toc">
6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">
6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">
6.2 Postmarketing Experience
</a></h2>
<h2><a href="#section-6.3" class="toc">
6.3 Clinical Laboratory Test Findings
</a></h2>
<h1><a href="#section-7" class="toc">
7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">
7.1 Diuretics
</a></h2>
<h2><a href="#section-7.2" class="toc">
7.2 Potassium Supplements and Potassium-Sparing Diuretics
</a></h2>
<h2><a href="#section-7.3" class="toc">
7.3 Lithium
</a></h2>
<h2><a href="#section-7.4" class="toc">
7.4 Gold
</a></h2>
<h2><a href="#section-7.5" class="toc">
7.5 Digoxin
</a></h2>
<h2><a href="#section-7.6" class="toc">
7.6 Gentamicin
</a></h2>
<h2><a href="#section-7.7" class="toc">
7.7 Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
</a></h2>
<h2><a href="#section-7.8" class="toc">
7.8 Dual Blockade of the Renin-Angiotensin System (RAS)
</a></h2>
<h1><a href="#section-8" class="toc">
8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">
8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">
8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">
8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">
8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">
8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-8.6" class="toc">
8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h1><a href="#section-9" class="toc">
10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">
11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">
12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">
12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">
12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">
12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">
13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">
14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-13.1" class="toc">
14.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</a></h2>
<h2><a href="#section-13.2" class="toc">
14.2 Stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span>
</a></h2>
<h1><a href="#section-14" class="toc">
16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">
17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="splSectionPLRBlackBox"></a><a name="section-1"></a><p></p>
<h1>
WARNING: FETAL TOXICITY
</h1>
<ul class="Disc">
<li>
<span class="Bold">When pregnancy is detected, discontinue ACEON as soon as possible.</span> (<a href="#splSection9">5.4</a>)</li>
<li>
<span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus.</span> (<a href="#splSection9">5.4</a>)</li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionPLRIndicationsUsage"></a><a name="section-1"></a><p></p>
<h1>
1 INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-1.1"></a><p></p>
<h2>
1.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</h2>
<p class="First">ACEON is indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span>. ACEON may be used alone or given with other classes of antihypertensives, especially thiazide diuretics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection2"></a><a name="section-1.2"></a><p></p>
<h2>
1.2 Stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span>
</h2>
<p class="First">ACEON is indicated for treatment of patients with stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> to reduce the risk of cardiovascular mortality or nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. ACEON can be used with conventional treatment for management of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, such as antiplatelet, antihypertensive or lipid-lowering therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionPLRDosageAdministration"></a><a name="section-2"></a><p></p>
<h1>
2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection3"></a><a name="section-2.1"></a><p></p>
<h2>
2.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</h2>
<p class="First"><span class="Bold Italics">Use in Uncomplicated Hypertensive Patients:</span>  In patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span>, the recommended initial dose is 4 mg once a day. The dose may be titrated, as needed to a maximum of 16 mg per day. The usual maintenance dose range is 4 mg to 8 mg administered as a single daily dose or in two divided doses.</p>
<p><span class="Bold Italics">Use in Elderly Patients:</span>  The recommended initial daily dosage of ACEON for the elderly is 4 mg daily, given in one or two divided doses. Experience with ACEON is limited in the elderly at doses exceeding 8 mg. Dosages above 8 mg should be administered with careful blood pressure monitoring and dose titration <span class="Italics">[see Use in Specific Populations (<a href="#splSectionPLRGeriatric">8.5</a>)]</span>.</p>
<p><span class="Bold Italics">Use with Diuretics:</span>  In patients who are currently being treated with a diuretic, symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> can occur following the initial dose of ACEON. Consider reducing the dose of diuretic prior to starting ACEON <span class="Italics">[see Drug Interactions (<a href="#splSection18">7.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection4"></a><a name="section-2.2"></a><p></p>
<h2>
2.2 Stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span>
</h2>
<p class="First">In patients with stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, ACEON should be given at an initial dose of 4 mg once daily for 2 weeks, and then increased as tolerated, to a maintenance dose of 8 mg once daily. In elderly patients (greater than 70 years), ACEON should be given as a 2 mg dose once daily in the first week, followed by 4 mg once daily in the second week and 8 mg once daily for maintenance dose if tolerated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection5"></a><a name="section-2.3"></a><p></p>
<h2>
2.3 Dose Adjustment in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> and Dialysis
</h2>
<p class="First">Perindoprilat elimination is decreased in renally impaired patients. ACEON is not recommended in patients with creatinine clearance &lt;30 mL/min. For patients with lesser degrees of impairment, the initial dosage should be 2 mg/day and dosage should not exceed 8 mg/day. During dialysis, perindopril is removed with the same clearance as in patients with normal renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="splSectionPLRDosageFormsStrength"></a><a name="section-3"></a><p></p>
<h1>
3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Tablets are oblong with a score on one side.</p>
<p>2 mg tablet is white and debossed on the unscored side with "ACN 2".</p>
<p>4 mg tablet is pink and debossed on the unscored side with "ACN 4".</p>
<p>8 mg tablet is salmon and debossed on the unscored side with "ACN 8".</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionPLRContraindications"></a><a name="section-4"></a><p></p>
<h1>
4 CONTRAINDICATIONS
</h1>
<p class="First">ACEON<span class="Sup">®</span> (perindopril erbumine) is contraindicated in patients known to be hypersensitive (including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to this product or to any other ACE inhibitor. ACEON is also contraindicated in patients with hereditary or idiopathic <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p>Do not co-administer aliskiren with ACEON in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. <span class="Italics">[see Drug Interactions (<a href="#splSection32">7.8</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="splSectionPLRWarnings"></a><a name="section-5"></a><p></p>
<h1>
5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection6"></a><a name="section-5.1"></a><p></p>
<h2>
5.1 Anaphylactoid and Possibly Related Reactions
</h2>
<p class="First">Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including ACEON) may be subject to a variety of adverse events, some of them serious. Black patients receiving ACE inhibitors have a higher incidence of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> compared to nonblacks.</p>
<p><span class="Bold Italics">Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>:</span>  <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> of the face, extremities, lips, tongue, glottis, or larynx has been reported in patients treated with ACE inhibitors, including ACEON (0.1% of patients treated with ACEON in U.S. clinical trials). <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with involvement of the tongue, glottis or larynx may be fatal. In such cases, discontinue ACEON treatment immediately and observe until the <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> disappears. When involvement of the tongue, glottis, or larynx appears likely to cause airway obstruction, administer appropriate therapy, such as subcutaneous epinephrine solution 1:1000 (0.3 to 0.5 mL), promptly.</p>
<p><span class="Bold Italics">Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>:</span>  Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> has been reported in patients treated with ACE inhibitors. These patients presented with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (with or without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>); in some cases there was no prior history of facial <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and C-1 esterase levels were normal. The <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> should be included in the differential diagnosis of patients on ACE inhibitors presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection7"></a><a name="section-5.2"></a><p></p>
<h2>
5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>
</h2>
<p class="First">ACEON can cause symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. ACEON has been associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in 0.3% of uncomplicated hypertensive patients in U.S. placebo-controlled trials. Symptoms related to <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> were reported in another 0.8% of patients.</p>
<p>Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is most likely to occur in patients who have been volume or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <span class="Italics">[see Dosage and Administration (<a href="#splSection3">2.1</a>)]</span>.</p>
<p>ACE inhibitors may cause excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and rarely with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. In patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span> or cerebrovascular disease, an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> could result in a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>.</p>
<p>In patients at risk of excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, ACEON therapy should be started under very close medical supervision. Patients should be followed closely for the first two weeks of treatment and whenever the dose of ACEON and/or diuretic is increased.</p>
<p>If excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patient should be placed immediately in a supine position and, if necessary, treated with an intravenous infusion of physiological saline. ACEON treatment can usually be continued following restoration of volume and blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection8"></a><a name="section-5.3"></a><p></p>
<h2>
5.3 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>
</h2>
<p class="First">ACE inhibitors have been associated with <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, most frequently in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, especially patients with a collagen vascular disease such as <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> or <span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">scleroderma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection9"></a><a name="section-5.4"></a><p></p>
<h2>
5.4 Fetal Toxicity
</h2>
<p class="First"><span class="Bold">Pregnancy Category D</span></p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected discontinue ACEON as soon as possible <span class="Italics">[see Use in Specific Populations (<a href="#splSectionPLRPregnancy">8.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection10"></a><a name="section-5.5"></a><p></p>
<h2>
5.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>
</h2>
<p class="First">As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. Renal function should be monitored periodically in patients receiving ACEON <span class="Italics">[see Dosage and Administration (<a href="#splSection5">2.3</a>)]</span>, <span class="Italics">[see Drug Interactions (<a href="#splSectionPLRDrugInteract">7</a>)]</span>.</p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, where renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors, including ACEON, may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and, rarely, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>In hypertensive patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in blood urea nitrogen and serum creatinine may occur; usually reversible upon discontinuation of the ACE inhibitor. In such patients, renal function should be monitored during the first few weeks of therapy.</p>
<p>Some ACEON-treated patients have developed minor and transient increases in blood urea nitrogen and serum creatinine especially in those concomitantly treated with a diuretic.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection11"></a><a name="section-5.6"></a><p></p>
<h2>
5.6 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>
</h2>
<p class="First">Elevations of serum potassium have been observed in some patients treated with ACE inhibitors, including ACEON. Most cases were isolated single values that did not appear clinically relevant and were rarely a cause for withdrawal. Risk factors for the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and the concomitant use of agents such as potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes <span class="Italics">[see Drug Interactions (<a href="#splSection19">7.2</a>)]</span>.</p>
<p>Serum potassium should be monitored periodically in patients receiving ACEON.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection12"></a><a name="section-5.7"></a><p></p>
<h2>
5.7 <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>
</h2>
<p class="First">Presumably because of the inhibition of the degradation of endogenous bradykinin, persistent nonproductive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> has been reported with all ACE inhibitors, generally resolving after discontinuation of therapy. Consider ACE inhibitor-induced <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection13"></a><a name="section-5.8"></a><p></p>
<h2>
5.8 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span>
</h2>
<p class="First">Rarely, ACE inhibitors have been associated with a syndrome that starts with <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and progresses to fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and sometimes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection14"></a><a name="section-5.9"></a><p></p>
<h2>
5.9 Surgery/Anesthesia
</h2>
<p class="First">In patients undergoing surgery or during anesthesia with agents that produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, ACEON may block angiotensin II formation that would otherwise occur secondary to compensatory renin release. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> attributable to this mechanism can be corrected by volume expansion.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionPLRAdverseReactions"></a><a name="section-6"></a><p></p>
<h1>
6 ADVERSE REACTIONS
</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection15"></a><a name="section-6.1"></a><p></p>
<h2>
6.1 Clinical Trials Experience
</h2>
<p class="First">The following adverse reactions are discussed elsewhere in labeling:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> <span class="Italics">[see Warnings and Precautions (<a href="#splSection6">5.1</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> <span class="Italics">[see Warnings and Precautions (<a href="#splSection7">5.2</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> <span class="Italics">[see Warnings and Precautions (<a href="#splSection8">5.3</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span> <span class="Italics">[see Warnings and Precautions (<a href="#splSection10">5.5</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> <span class="Italics">[see Warnings and Precautions (<a href="#splSection11">5.6</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> <span class="Italics">[see Warnings and Precautions (<a href="#splSection12">5.7</a>)]</span>
</li>
</ul>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>ACEON has been evaluated for safety in approximately 3,400 patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in U.S. and foreign clinical trials. The data presented here are based on results from the 1,417 ACEON-treated patients who participated in the U.S. clinical trials. Over 220 of these patients were treated with ACEON<span class="Sup">®</span> (perindopril erbumine) for at least one year.</p>
<p>In placebo-controlled U.S. clinical trials, the incidence of premature discontinuation of therapy due to adverse events was 6.5% in patients treated with ACEON and 6.7% in patients treated with placebo. The most common causes were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>Among 1,012 patients in placebo-controlled U.S. trials, the overall frequency of reported adverse events was similar in patients treated with ACEON and in those treated with placebo (approximately 75% in each group). The only adverse events whose incidence on ACEON was at least 2% greater than on placebo were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (12% vs. 4.5%) and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (5.8% vs. 3.1%).</p>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> was not reported more frequently in the perindopril group (8.2%) than in the placebo group (8.5%), but its likelihood increased with dose, suggesting a causal relationship with perindopril.</p>
<p><span class="Italics Underline">Stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span></span></p>
<p>Perindopril has been evaluated for safety in EUROPA, a double-blind, placebo-controlled study in 12,218 patients with stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. The overall rate of discontinuation was about 22% on drug and placebo. The most common medical reasons for discontinuation that were more frequent on perindopril than placebo were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4240582" conceptname="Drug intolerance">drug intolerance</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection16"></a><a name="section-6.2"></a><p></p>
<h2>
6.2 Postmarketing Experience
</h2>
<p class="First">Voluntary reports of adverse events in patients taking ACEON that have been received since market introduction and are of unknown causal relationship to ACEON include: <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (including hemolytic and aplastic), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (hepatocellular or cholestatic), symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="139899" conceptname="Pemphigoid">bullous pemphigoid</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> and a syndrome which may include: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>/<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4157025" conceptname="Serositis">serositis</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other dermatologic manifestations, a positive <span class="product-label-link" type="condition" conceptid="4163958" conceptname="Antinuclear antibody">antinuclear antibody</span> (ANA), <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> or an elevated <span class="product-label-link" type="condition" conceptid="434481" conceptname="Erythrocyte sedimentation rate - finding">erythrocyte sedimentation rate</span> (ESR).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection17"></a><a name="section-6.3"></a><p></p>
<h2>
6.3 Clinical Laboratory Test Findings
</h2>
<p class="First"><span class="Bold Italics">Hematology:</span>  Small decreases in hemoglobin and hematocrit occur frequently in hypertensive patients treated with ACEON, but are rarely of clinical importance. In controlled clinical trials, no patient was discontinued from therapy due to the development of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> (including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>) was observed in 0.1% of patients in U.S. clinical trials <span class="Italics">[see Warnings and Precautions (<a href="#splSection8">5.3</a>)]</span>.</p>
<p><span class="Bold Italics">Liver Function Tests:</span>  Elevations in ALT (1.6% ACEON versus 0.9% placebo) and AST (0.5% ACEON versus 0.4% placebo) have been observed in placebo-controlled clinical trials. The elevations were generally mild and transient and resolved after discontinuation of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPLRDrugInteract"></a><a name="section-7"></a><p></p>
<h1>
7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection18"></a><a name="section-7.1"></a><p></p>
<h2>
7.1 Diuretics
</h2>
<p class="First">Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON therapy. The possibility of hypotensive effects can be minimized by either decreasing the dose of or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril. If diuretic therapy cannot be altered, provide close medical supervision with the first dose of ACEON, for at least two hours and until blood pressure has stabilized for another hour <span class="Italics">[see Warnings and Precautions (<a href="#splSection7">5.2</a>)]</span>.</p>
<p>The rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics. The bioavailability of perindoprilat was reduced by diuretics, however, and this was associated with a decrease in plasma ACE inhibition.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection19"></a><a name="section-7.2"></a><p></p>
<h2>
7.2 Potassium Supplements and Potassium-Sparing Diuretics
</h2>
<p class="First">ACEON may increase serum potassium because of its potential to decrease aldosterone production. Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection20"></a><a name="section-7.3"></a><p></p>
<h2>
7.3 Lithium
</h2>
<p class="First">Increased serum lithium and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. Frequent monitoring of serum lithium concentration is recommended. Use of a diuretic may further increase the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection21"></a><a name="section-7.4"></a><p></p>
<h2>
7.4 Gold
</h2>
<p class="First">Nitritoid reactions (symptoms include <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE Inhibitor therapy including ACEON.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection22"></a><a name="section-7.5"></a><p></p>
<h2>
7.5 Digoxin
</h2>
<p class="First">A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection23"></a><a name="section-7.6"></a><p></p>
<h2>
7.6 Gentamicin
</h2>
<p class="First">Animal data have suggested the possibility of interaction between perindopril and gentamicin. However, this has not been investigated in human studies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection31"></a><a name="section-7.7"></a><p></p>
<h2>
7.7 Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
</h2>
<p class="First">In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including perindopril, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. These effects are usually reversible. Monitor renal function periodically in patients receiving perindopril and NSAID therapy.</p>
<p>The antihypertensive effect of ACE inhibitors, including perindopril, may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection32"></a><a name="section-7.8"></a><p></p>
<h2>
7.8 Dual Blockade of the Renin-Angiotensin System (RAS)
</h2>
<p class="First">Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and changes in renal function (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on ACEON and other agents that affect the RAS.</p>
<p>Do not co-administer aliskiren with ACEON in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Avoid use of aliskiren with ACEON in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt;60 ml/min).</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="splSectionPLRPopulations"></a><a name="section-8"></a><p></p>
<h1>
8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPLRPregnancy"></a><a name="section-8.1"></a><p></p>
<h2>
8.1 Pregnancy
</h2>
<p class="First">Pregnancy Category D [<span class="Italics">see <a href="#splSectionPLRBlackBox">Boxed Warning</a> and Warnings and Precautions (<a href="#splSection9">5.4</a>)</span>].</p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue ACEON as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy is important to optimize outcomes for both mother and fetus.</p>
<p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, discontinue ACEON, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to ACEON for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> <span class="Italics">[see Use in Specific Populations (<a href="#splSectionPLRPediatric">8.4</a>)]</span>.</p>
<p>Radioactivity was detectable in fetuses after administration of <span class="Sup">14</span>C-perindopril to pregnant rats.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPLRNursing"></a><a name="section-8.2"></a><p></p>
<h2>
8.3 Nursing Mothers
</h2>
<p class="First">Milk of lactating rats contained radioactivity following administration of <span class="Sup">14</span>C-perindopril. It is not known whether perindopril is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when ACEON is given to nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPLRPediatric"></a><a name="section-8.3"></a><p></p>
<h2>
8.4 Pediatric Use
</h2>
<p class="First"><span class="Underline">Neonates with a history of in utero exposure to ACEON:</span></p>
<p>If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function. Perindopril, which crosses the placenta, can theoretically be removed from the neonatal circulation by these means, but limited experience has not shown that such removal is central to the treatment of these infants.</p>
<p>Safety and effectiveness of ACEON in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPLRGeriatric"></a><a name="section-8.4"></a><p></p>
<h2>
8.5 Geriatric Use
</h2>
<p class="First">The mean blood pressure effect of perindopril was somewhat smaller in patients over 60 than in younger patients, although the difference was not significant. Plasma concentrations of both perindopril and perindoprilat were increased in elderly patients compared to concentrations in younger patients. No adverse effects were clearly increased in older patients with the exception of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and possibly <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>Start at a low dose and titrate slowly as needed. Monitor for <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> because of potential for <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>.</p>
<p>Experience with ACEON in elderly patients at daily doses exceeding 8 mg is limited.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection25"></a><a name="section-8.5"></a><p></p>
<h2>
8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Dosage adjustment may be necessary in renally impaired patients <span class="Italics">[see Dosage and Administration (<a href="#splSection5">2.3</a>) and Clinical Pharmacology (<a href="#splSectionPLRPharmacokinetics">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection26"></a><a name="section-8.6"></a><p></p>
<h2>
8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">The bioavailability of perindoprilat is increased in patients with impaired hepatic function <span class="Italics">[see Clinical Pharmacology (<a href="#splSectionPLRPharmacokinetics">12.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionPLROverdose"></a><a name="section-9"></a><p></p>
<h1>
10 OVERDOSAGE
</h1>
<p class="First">In animals, doses of perindopril up to 2,500 mg/kg in mice, 3,000 mg/kg in rats and 1,600 mg/kg in dogs were non-lethal. Past experiences were scant but suggested that overdosage with other ACE inhibitors was also fairly well tolerated by humans. The most likely manifestation is <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and treatment should be symptomatic and supportive. Therapy with the ACE inhibitor should be discontinued, and the patient should be observed. <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should be treated by established procedures.</p>
<p>Among the reported cases of perindopril overdosage, patients who were known to have ingested a dose of 80 mg to 120 mg required assisted ventilation and circulatory support. One additional patient developed <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, circulatory arrest and died following ingestion of up to 180 mg of perindopril. The intervention for perindopril <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may require vigorous support.</p>
<p>Laboratory determinations of serum levels of perindopril and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of perindopril <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>No data are available to suggest physiological maneuvers (<span class="Italics">e.g.</span>, maneuvers to change the pH of the urine) that might accelerate elimination of perindopril and its metabolites. Perindopril can be removed by hemodialysis, with clearance of 52 mL/min for perindopril and 67 mL/min for perindoprilat.</p>
<p>Angiotensin II could presumably serve as a specific antagonist-antidote in the settling of perindopril <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, but angiotensin II is essentially unavailable outside of scattered research facilities. Because the hypotensive effect of perindopril is achieved through vasodilation and effective <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, it is reasonable to treat perindopril <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> by infusion of normal saline solution.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionPLRDescription"></a><a name="section-10"></a><p></p>
<h1>
11 DESCRIPTION
</h1>
<p class="First">ACEON<span class="Sup">®</span> (perindopril erbumine) Tablets contain the tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Perindopril erbumine is chemically described as (2S,3?S,7?S)-1-[(S)-N-[(S)-1-Carboxy-butyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1). Its molecular formula is C<span class="Sub">19</span>H<span class="Sub">32</span>N<span class="Sub">2</span>O<span class="Sub">5</span>C<span class="Sub">4</span>H<span class="Sub">11</span>N. Its structural formula is:</p>
<div class="Figure"><img alt="
aceon-01
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=340846a3-896e-40bf-a4d0-419922df71a1&amp;name=ace0h-0000-01.jpg"></div>
<p>Perindopril erbumine is a white, crystalline powder with a molecular weight of 368.47 (free acid) or 441.61 (salt form). It is freely soluble in water (60% w/w), alcohol and chloroform.</p>
<p>Perindopril is the free acid form of perindopril erbumine, is a pro-drug and metabolized <span class="Italics">in vivo</span> by hydrolysis of the ester group to form perindoprilat, the biologically active metabolite.</p>
<p>ACEON is available in 2 mg, 4 mg and 8 mg strengths for oral administration. In addition to perindopril erbumine, each tablet contains the following inactive ingredients: colloidal silica (hydrophobic), lactose, magnesium stearate and microcrystalline cellulose. The 4 mg and 8 mg tablets also contain iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionPLRClinicalPharm"></a><a name="section-11"></a><p></p>
<h1>
12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="splSectionPLRMechAction"></a><a name="section-11.1"></a><p></p>
<h2>
12.1 Mechanism of Action
</h2>
<p class="First">ACEON<span class="Sup">®</span> (perindopril erbumine) is a pro-drug for perindoprilat, which inhibits ACE in human subjects and animals. The mechanism through which perindoprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes conversion of the inactive decapeptide, angiotensin I, to the vasoconstrictor, angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor, which stimulates aldosterone secretion by the adrenal cortex, and provides negative feedback on renin secretion. Inhibition of ACE results in decreased plasma angiotensin II, leading to decreased <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, increased plasma renin activity and decreased aldosterone secretion. The latter results in <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and natriuresis and may be associated with a small increase of serum potassium.</p>
<p>ACE is identical to kininase II, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of ACEON remains to be elucidated.</p>
<p>While the principal mechanism of perindopril in blood pressure reduction is believed to be through the renin-angiotensin-aldosterone system, ACE inhibitors have some effect even in apparent low-renin <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Perindopril has been studied in relatively few black patients, usually a low-renin population, and the average response of diastolic blood pressure to perindopril was about half the response seen in nonblack patients, a finding consistent with previous experience of other ACE inhibitors.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="splSectionPLRPharmacodynamics"></a><a name="section-11.2"></a><p></p>
<h2>
12.2 Pharmacodynamics
</h2>
<p class="First">After administration of perindopril, ACE is inhibited in a dose and blood concentration-related fashion, with the maximal inhibition of 80 to 90% attained by 8 mg persisting for 10 to 12 hours. Twenty-four hour ACE inhibition is about 60% after these doses. The degree of ACE inhibition achieved by a given dose appears to diminish over time (the ID<span class="Sub">50</span> increases). The pressor response to an angiotensin I infusion is reduced by perindopril, but this effect is not as persistent as the effect on ACE; there is about 35% inhibition at 24 hours after a 12 mg dose.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="splSectionPLRPharmacokinetics"></a><a name="section-11.3"></a><p></p>
<h2>
12.3 Pharmacokinetics
</h2>
<p class="First"><span class="Bold Italics">Absorption:</span>  Oral administration of ACEON results in peak plasma concentrations that occur at approximately 1 hour. The absolute oral bioavailability of perindopril is about 75%. Following absorption, approximately 30 to 50% of systemically available perindopril is hydrolyzed to its active metabolite, perindoprilat, which has a mean bioavailability of about 25%. Peak plasma concentrations of perindoprilat are attained 3 to 7 hours after perindopril administration. Oral administration of ACEON with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state. However, the extent of biotransformation of perindopril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. In clinical trials, perindopril was generally administered in a non-fasting state.</p>
<p>With 4 mg, 8 mg and 16 mg doses of ACEON, C<span class="Sub">max</span> and AUC of perindopril and perindoprilat increase in a dose-proportional manner following both single oral dosing and at steady state during a once-a-day multiple dosing regimen.</p>
<p><span class="Bold Italics">Distribution:</span>  Approximately 60% of circulating perindopril is bound to plasma proteins, and only 10 to 20% of perindoprilat is bound. Therefore, drug interactions mediated through effects on protein binding are not anticipated.</p>
<p><span class="Bold Italics">Metabolism and Elimination:</span>  Following oral administration perindopril exhibits multicompartment pharmacokinetics including a deep tissue compartment (ACE binding sites). The mean half-life of perindopril associated with most of its elimination is approximately 0.8 to 1 hours.</p>
<p>Perindopril is extensively metabolized following oral administration, with only 4 to 12% of the dose recovered unchanged in the urine. Six metabolites resulting from hydrolysis, glucuronidation and cyclization via <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> have been identified. These include the active ACE inhibitor, perindoprilat (hydrolyzed perindopril), perindopril and perindoprilat glucuronides, dehydrated perindopril and the diastereoisomers of dehydrated perindoprilat. In humans, hepatic esterase appears to be responsible for the hydrolysis of perindopril.</p>
<p>The active metabolite, perindoprilat, also exhibits multicompartment pharmacokinetics following the oral administration of ACEON. Formation of perindoprilat is gradual with peak plasma concentrations occurring between 3 and 7 hours. The subsequent decline in plasma concentration shows an apparent mean half-life of 3 to 10 hours for the majority of the elimination, with a prolonged terminal elimination half-life of 30 to 120 hours resulting from slow dissociation of perindoprilat from plasma/tissue ACE binding sites. During repeated oral once daily dosing with perindopril, perindoprilat accumulates about 1.5 to 2 fold and attains steady state plasma levels in 3 to 6 days. The clearance of perindoprilat and its metabolites is almost exclusively renal.</p>
<p><span class="Bold Italics">Elderly:</span>  Plasma concentrations of both perindopril and perindoprilat in elderly patients (greater than 70 years) are approximately twice those observed in younger patients, reflecting both increased conversion of perindopril to perindoprilat and decreased renal excretion of perindoprilat <span class="Italics">[see Dosage and Administration (<a href="#splSection3">2.1</a>) and Use In Specific Populations (<a href="#splSectionPLRGeriatric">8.5</a>)]</span>.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>:</span>  Perindoprilat clearance is reduced in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> patients, resulting in a 40% higher dose interval AUC.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span>  With perindopril doses of 2 mg to 4 mg, perindoprilat AUC increases with decreasing renal function. At creatinine clearances of 30 to 80 mL/min, AUC is about double that at 100 mL/min. When creatinine clearance drops below 30 mL/min, AUC increases more markedly.</p>
<p>In a limited number of patients studied, perindopril clearance by dialysis ranged from about 40 to 80 mL/min. Perindoprilat clearance by dialysis ranged from about 40 to 90 mL/min <span class="Italics">[see Dosage and Administration (<a href="#splSection5">2.3</a>)]</span>.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span>  The bioavailability of perindoprilat is increased in patients with impaired hepatic function. Plasma concentrations of perindoprilat in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span> were about 50% higher than those observed in healthy subjects or hypertensive patients with normal liver function.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="splSectionPLRNonClinical"></a><a name="section-12"></a><p></p>
<h1>
13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPLRPrecautionsCarcinogen"></a><a name="section-12.1"></a><p></p>
<h2>
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First"><span class="Bold Italics">Carcinogenicity:</span>  No evidence of carcinogenic effect was observed in studies in rats and mice when perindopril was administered at dosages up to 20 times (mg/kg) or 2 to 4 times (mg/m<span class="Sup">2</span>) the maximum proposed clinical doses (16 mg/day) for 104 weeks.</p>
<p><span class="Bold Italics">Mutagenesis:</span>  No genotoxic potential was detected for ACEON, perindoprilat and other metabolites in various <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> investigations, including the Ames test, the <span class="Italics">Saccharomyces cerevisiae</span> D4 test, cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, TK ± mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, mouse and rat micronucleus tests and Chinese hamster bone marrow assay.</p>
<p><span class="Bold Italics">Impairment of Fertility:</span>  There was no meaningful effect on reproductive performance or fertility in the rat given up to 30 times (mg/kg) or 6 times (mg/m<span class="Sup">2</span>) the proposed maximum clinical dosage of ACEON during the period of spermatogenesis in males or oogenesis and gestation in females.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="splSectionPLRClinicalStudies"></a><a name="section-13"></a><p></p>
<h1>
14 CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection27"></a><a name="section-13.1"></a><p></p>
<h2>
14.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</h2>
<p class="First">In placebo-controlled studies of perindopril monotherapy (2 mg to 16 mg once daily) in patients with a mean blood pressure of about 150/100 mm Hg, 2 mg had little effect, but doses of 4 mg to 16 mg <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">lowered blood pressure</span>. The 8 mg and 16 mg doses were indistinguishable, and both had a greater effect than the 4 mg dose. In these studies, doses of 8 mg and 16 mg per day gave supine, trough blood pressure reductions of 9 to 15/5 to 6 mm Hg. When once daily and twice daily dosing were compared, the twice daily dosing regimen was generally slightly superior, but by not more than about 0.5 mm Hg to 1 mm Hg. After 2 mg to 16 mg doses of perindopril, the trough mean systolic and diastolic blood pressure effects were about 75 to 100% of peak effects.</p>
<p>Perindopril's effects on blood pressure were similar when given alone or on a background of 25 mg hydrochlorothiazide In general, the effect of perindopril occurred promptly, with effects increasing slightly over several weeks.</p>
<p>Formal interaction studies of ACEON<span class="Sup">®</span> (perindopril erbumine) have not been carried out with antihypertensive agents other than thiazides. Limited experience in controlled and uncontrolled trials coadministering ACEON with a calcium channel blocker, a loop diuretic or triple therapy (beta-blocker, vasodilator and a diuretic), does not suggest any unexpected interactions. In general, ACE inhibitors have less than additive effects when given with beta-adrenergic blockers, presumably because both work in part through the renin angiotensin system.</p>
<p>In uncontrolled studies in patients with insulin-dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, perindopril did not appear to affect glycemic control. In long-term use, no effect on urinary protein excretion was seen in these patients.</p>
<p>The effectiveness of ACEON was not influenced by sex and it was less effective in black patients than in nonblack patients. In elderly patients (greater than or equal to 60 years), the mean blood pressure effect was somewhat smaller than in younger patients, although the difference was not significant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection28"></a><a name="section-13.2"></a><p></p>
<h2>
14.2 Stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span>
</h2>
<p class="First">The EURopean trial On reduction of cardiac events with Perindopril in stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary Artery disease</span> (EUROPA) was a multicenter, randomized, double-blind and placebo-controlled study conducted in 12,218 patients who had evidence of stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> without clinical <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Patients had evidence of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> documented by previous <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> more than 3 months before screening, coronary revascularization more than 6 months before screening, angiographic evidence of stenosis (at least 70% narrowing of one or more major coronary arteries), or positive stress test in men with a history of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>. After a run-in period of 4 weeks during which all patients received perindopril 2 mg to 8 mg, the patients were randomly assigned to perindopril 8 mg once daily (n=6,110) or matching placebo (n=6,108). The mean follow-up was 4.2 years. The study examined the long-term effects of perindopril on time to first event of cardiovascular mortality, nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> in patients with stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
<p>The mean age of patients was 60 years; 85% were male, 92% were taking platelet inhibitors, 63% were taking β blockers, and 56% were taking lipid-lowering therapy. The EUROPA study showed that perindopril significantly reduced the relative risk for the primary endpoint events (Table 1). This beneficial effect is largely attributable to a reduction in the risk of nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. This beneficial effect of perindopril on the primary outcome was evident after about one year of treatment (Figure 1). The outcome was similar across all predefined subgroups by age, underlying disease or concomitant medication (Figure 2).</p>
<table width="80%">
<caption><span>
Table 1. Primary Endpoint and Relative Risk Reduction
</span></caption>
<col align="left" width="36%">
<col align="center" width="16%">
<col align="center" width="16%">
<col align="center" width="16%">
<col align="center" width="16%">
<tfoot><tr class="First Last"><td align="left" colspan="5"><span class="Italics">CI=confidence interval; RRR: relative risk reduction; MI: <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></span></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="left"><span class="Bold"> </span></td>
<td class="Botrule" align="center">
<span class="Bold">Perindopril</span><br><span class="Bold">(N = 6,110)</span>
</td>
<td class="Botrule" align="center">
<span class="Bold">Placebo</span><br><span class="Bold">(N = 6,108)</span>
</td>
<td class="Botrule" align="center">
<span class="Bold">RRR</span><br><span class="Bold">(95% CI)</span>
</td>
<td class="Botrule" align="center"><span class="Bold">P</span></td>
</tr>
<tr>
<td align="left"><span class="Bold">Combined Endpoint</span></td>
<td align="center">
 
</td>
<td align="center">
 
</td>
<td align="center">
 
</td>
<td align="center">
 
</td>
</tr>
<tr>
<td align="left">
  Cardiovascular mortality, nonfatal MI or <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>
</td>
<td align="center">
488 (8%)
</td>
<td align="center">
603 (9.9%)
</td>
<td align="center">
20% (9 to 29)
</td>
<td align="center">
0.0003
</td>
</tr>
<tr>
<td align="left"><span class="Bold">Component Endpoint</span></td>
<td align="center">
 
</td>
<td align="center">
 
</td>
<td align="center">
 
</td>
<td align="center">
 
</td>
</tr>
<tr>
<td align="left">
  Cardiovascular mortality
</td>
<td align="center">
215 (3.5%)
</td>
<td align="center">
249 (4.1%)
</td>
<td align="center">
14% (-3 to 28)
</td>
<td align="center">
0.107
</td>
</tr>
<tr>
<td align="left">
  Nonfatal MI
</td>
<td align="center">
295 (4.8%)
</td>
<td align="center">
378 (6.2%)
</td>
<td align="center">
22% (10 to 33)
</td>
<td align="center">
0.001
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left">
  <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>
</td>
<td class="Botrule" align="center">
6 (0.1%)
</td>
<td class="Botrule" align="center">
11 (0.2%)
</td>
<td class="Botrule" align="center">
46% (-47 to 80)
</td>
<td class="Botrule" align="center">
0.22
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 1. Time to First Occurrence of Primary Endpoint</span></p>
<div class="Figure"><img alt="
aceon-02
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=340846a3-896e-40bf-a4d0-419922df71a1&amp;name=ace0h-0000-02.jpg"></div>
<p><span class="Bold">Figure 2. Beneficial Effect of Perindopril Treatment on Primary Endpoint in Predefined Subgroups</span></p>
<div class="Figure"><img alt="
aceon-03
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=340846a3-896e-40bf-a4d0-419922df71a1&amp;name=ace0h-0000-03.jpg"></div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionPLRHowSupplied"></a><a name="section-14"></a><p></p>
<h1>
16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">Tablets are oblong with a score on one side.</p>
<table width="80%">
<col align="center" width="20%">
<col align="center" width="45%">
<col align="center" width="35%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center"><span class="Bold">Tablets</span></td>
<td class="Botrule" align="center"><span class="Bold">Appearance</span></td>
<td class="Botrule" align="center"><span class="Bold">NDC (Bottles of 100)</span></td>
</tr>
<tr>
<td class="Botrule" align="center">
2 mg
</td>
<td class="Botrule" align="center">
White, debossed "ACN 2" on unscored side
</td>
<td class="Botrule" align="center">
NDC 61894-000-02
</td>
</tr>
<tr>
<td class="Botrule" align="center">
4 mg
</td>
<td class="Botrule" align="center">
Pink, debossed "ACN 4" on unscored side
</td>
<td class="Botrule" align="center">
NDC 61894-001-02
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">
8 mg
</td>
<td class="Botrule" align="center">
Salmon-colored, debossed "ACN 8" on unscored side
</td>
<td class="Botrule" align="center">
NDC 61894-002-02
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Keep out of the reach of children.</span></p>
<p>Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP]. Protect from moisture.</p>
<p><a name="f04"></a><img alt="Telephone
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=340846a3-896e-40bf-a4d0-419922df71a1&amp;name=ace0h-0000-04.jpg">For further information, please call our medical communications department toll-free at 888-985-7657.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPLRPatientInfo"></a><a name="section-15"></a><p></p>
<h1>
17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Female patients of childbearing age should be told about the consequences of exposure to ACEON during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.</p>
<p>Tell patients to report promptly any indication of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<span class="Italics">e.g.</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) which could be a sign of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p><br><span class="Bold">Manufactured by:</span><br>Patheon Pharmaceuticals, Inc.<br>Cincinnati, OH 45237 USA</p>
<p><span class="Bold">Marketed by:</span><br>Symplmed, LLC. <br>Cincinnati, OH 45227 USA</p>
<p>3-030615.9 </p>
<p>Rev Jan 2015 </p>
<p>70029867</p>
<p>Revised: 03, 2015</p>
<p><span class="Bold">symplmed™</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s3"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL –2mg 100 Tablet Bottle Label</span></p>
<p>100 Tablets
</p>
<p>NDC 61894-000-02
</p>
<p><span class="Bold">Aceon</span><span class="Bold"><span class="Sup">®</span></span></p>
<p>perindopril erbumine Tablets
</p>
<p>2mg
</p>
<p>Rx ONLY
</p>
<p>Keep out of reach of children
</p>
<p>symplmed™
</p>
<div class="Figure">
<a name="f05"></a><img alt="PRINCIPAL DISPLAY PANEL –2mg 100 Tablet Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=340846a3-896e-40bf-a4d0-419922df71a1&amp;name=ace0h-0000-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s4"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL –4mg 100 Tablet Bottle Label</span></p>
<p>100 Tablets
</p>
<p>NDC 61894-001-02
</p>
<p><span class="Bold">Aceon</span><span class="Bold"><span class="Sup">®</span></span></p>
<p>perindopril erbumine Tablets
</p>
<p>4mg
</p>
<p>Rx ONLY
</p>
<p>Keep out of reach of children
</p>
<p>symplmed™
</p>
<div class="Figure">
<a name="f06"></a><img alt="PRINCIPAL DISPLAY PANEL –4mg 100 Tablet Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=340846a3-896e-40bf-a4d0-419922df71a1&amp;name=ace0h-0000-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s5"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL –8mg 100 Tablet Bottle Label</span></p>
<p>100 Tablets
</p>
<p>NDC 61894-002-02
</p>
<p><span class="Bold">Aceon</span><span class="Bold"><span class="Sup">®</span></span></p>
<p>perindopril erbumine Tablets
</p>
<p>8mg
</p>
<p>Rx ONLY
</p>
<p>Keep out of reach of children
</p>
<p>symplmed™
</p>
<div class="Figure">
<a name="f07"></a><img alt="PRINCIPAL DISPLAY PANEL –8mg 100 Tablet Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=340846a3-896e-40bf-a4d0-419922df71a1&amp;name=ace0h-0000-07.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACEON 		
					</strong><br><span class="contentTableReg">perindopril erbumine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61894-000</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>perindopril erbumine</strong> (perindoprilat) </td>
<td class="formItem">perindopril erbumine</td>
<td class="formItem">2 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACN;2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61894-000-02</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020184</td>
<td class="formItem">10/10/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACEON 		
					</strong><br><span class="contentTableReg">perindopril erbumine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61894-001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>perindopril erbumine</strong> (perindoprilat) </td>
<td class="formItem">perindopril erbumine</td>
<td class="formItem">4 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink (pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACN;4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61894-001-02</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020184</td>
<td class="formItem">10/10/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACEON 		
					</strong><br><span class="contentTableReg">perindopril erbumine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61894-002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>perindopril erbumine</strong> (perindoprilat) </td>
<td class="formItem">perindopril erbumine</td>
<td class="formItem">8 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">red (salmon) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACN;8</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61894-002-02</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020184</td>
<td class="formItem">10/10/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Symplmed, LLC
							(079198402)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Oril Industrie</td>
<td class="formItem"></td>
<td class="formItem">501890719</td>
<td class="formItem">API MANUFACTURE(61894-000, 61894-001, 61894-002)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">005286822</td>
<td class="formItem">MANUFACTURE(61894-000, 61894-001, 61894-002), ANALYSIS(61894-000, 61894-001, 61894-002), PACK(61894-000, 61894-001, 61894-002), LABEL(61894-000, 61894-001, 61894-002)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8adb66b3-d0cc-472d-9ca2-4299952189fb</div>
<div>Set id: 340846a3-896e-40bf-a4d0-419922df71a1</div>
<div>Version: 4</div>
<div>Effective Time: 20150508</div>
</div>
</div> <div class="DistributorName">Symplmed, LLC</div></p>
</body></html>
